Swiss pharmaceutical company Novartis announced Tuesday that it had discontinued the development of two drugs — the hepatitis C treatment Zalbin, and antifungal agent Mycograb. The company will take impairment charges of appro…
Novartis (NVS) agreed to sell the U.S. rights to bladder medicine Enablex for $400 million.
Ireland-based Warner Chilcott will take over the marketing, sales and manufacturing of the drug in the United States, Novartis said in a statement. The deal is expected to close by the end of October.
Novartis may also receive “milestone payments” of as much as $20 million.
In 2005, Novartis…
Continue reading Novartis Sells U.S. Rights to Enablex for $400 Million
Novartis Sells U.S. Rights to Enablex for $400 Million originally appeared on DailyFinance on Fri, 24 Sep 2010 06:46:00.
Filed Under: Company News, Health Care, Novartis, Insurance, Retail
After a long wait, the FDA has OK’d Novartis’s Gilenya as a first-line treatment for relapsing forms of multiple sclerosis — the disease’s most common form. MS affects over 400,000 Americans and more than 2.1 million people wo…
Shares of Swiss pharmaceutical company Novartis were up about 1.5% in morning trading Monday following its announcement over the weekend that its Onbrez Breezhaler was found to be more effective at treating lung disease than a…